Market Access GSK’s Nucala secures NICE COPD endorsement Pharmaceutical TechnologyNICE now recommends Nucala for both severe asthma and COPD, expanding the drug's clinical uptake across the UK's public health service.RespiratoryRead full story pharminent May 29, 2026 (Last updated: May 29, 2026) Pharmaceutical Technology NICE now recommends Nucala for both severe asthma and COPD, expanding the drug’s clinical uptake across the UK’s public health service. Respiratory Read full story Post navigation Previous: Ahead of ASCO data drop, AZ gets key Imfinzi approvalNext: Pfizer bets up to $10.5B in 12-candidate cancer collab with China’s Innovent Related Stories Market Access How cost and perception could reshape the GLP-1 market pharminent August 21, 2026 Market Access D.C. Circuit Affirms HHS Authority Over 340B Rebate Models pharminent July 24, 2026 Market Access NICE aims to cut funding for Amgen lung cancer drug Lumykras pharminent July 9, 2026
